{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:36:19Z","timestamp":1792985779164,"version":"4.5.0"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.critrevonc.2025.104897","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T06:43:46Z","timestamp":1755153826000},"page":"104897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The role of the major histocompatibility complex (MHC) class I in prostate cancer therapy: A review"],"prefix":"10.1016","volume":"215","author":[{"given":"Nikoo","family":"Emtiazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Zolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhood Khaleghi","family":"Mehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasaman","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.critrevonc.2025.104897_bib1","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4161\/epi.3.6.7273","article-title":"The role of histone deacetylases in prostate cancer","volume":"3","author":"Abbas","year":"2008","journal-title":"Epigenetics"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104897_bib2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10555-021-09964-4","article-title":"MHC heterogeneity and response of metastases to immunotherapy","volume":"40","author":"Algarra","year":"2021","journal-title":"Cancer Metastas.. Rev."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104897_bib3","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1178439","article-title":"MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4+ T-cells","volume":"5","author":"Anastasopoulou","year":"2016","journal-title":"Oncoimmunology"},{"issue":"49","key":"10.1016\/j.critrevonc.2025.104897_bib4","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2314416120","article-title":"Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy","volume":"120","author":"Bao","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104897_bib5","doi-asserted-by":"crossref","first-page":"454","DOI":"10.21037\/tau-24-382","article-title":"DNA methylation alterations in prostate cancer: from diagnosis to treatment","volume":"14","author":"Barletta","year":"2025","journal-title":"Transl. Androl. Urol."},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104897_bib6","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1158\/1078-0432.CCR-17-0019","article-title":"Immunotherapy of prostate cancer: facts and hopes","volume":"23","author":"Bilusic","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104897_bib7","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0090-4295(99)80301-X","article-title":"Loss of HLA class I expression in prostate cancer: implications for immunotherapy","volume":"46","author":"Blades","year":"1995","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104897_bib8","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1146\/annurev-immunol-032712-095910","article-title":"Pathways of antigen processing","volume":"31","author":"Blum","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104897_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-020-07058-y","article-title":"Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy","volume":"20","author":"Bou-Dargham","year":"2020","journal-title":"BMC Cancer"},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104897_bib10","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2321600121","article-title":"Dual role of the peptide-loading complex as proofreader and limiter of MHC-I presentation","volume":"121","author":"Brunnberg","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104897_bib11","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","article-title":"An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer","volume":"36","author":"Burr","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104897_bib12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00018-024-05201-7","article-title":"iRhom2 regulates ectodomain shedding and surface expression of the major histocompatibility complex (MHC) class I","volume":"81","author":"Calligaris","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104897_bib13","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1158\/0008-5472.CAN-19-2948","article-title":"Revisiting immunotherapy: a focus on prostate cancer","volume":"80","author":"Cha","year":"2020","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104897_bib14","doi-asserted-by":"crossref","first-page":"328","DOI":"10.14348\/molcells.2021.0052","article-title":"MHC multimer: a molecular toolbox for immunologists","volume":"44","author":"Chang","year":"2021","journal-title":"Mol. Cells"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104897_bib15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/mas.21616","article-title":"Identification of MHC peptides using mass spectrometry for neoantigen discovery and cancer vaccine development","volume":"40","author":"Chen","year":"2021","journal-title":"Mass Spectrom. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104897_bib16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-025-01722-1","article-title":"Application of single-cell and spatial omics in deciphering cellular hallmarks of cancer drug response and resistance","volume":"18","author":"Cheng","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104897_bib17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1158\/2159-8290.CD-24-0559","article-title":"Androgen receptor inhibition increases MHC class I expression and improves immune response in prostate cancer","volume":"15","author":"Chesner","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.104897_bib18","doi-asserted-by":"crossref","unstructured":"Chesner, L.N., et al., AR inhibition increases MHC class I expression and improves immune response in prostate cancer. 2023.","DOI":"10.2139\/ssrn.4403436"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104897_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/2051013614525375","article-title":"MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines","volume":"2","author":"Comber","year":"2014","journal-title":"Ther. Adv. Vaccin."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104897_bib20","doi-asserted-by":"crossref","first-page":"1700259","DOI":"10.1002\/pmic.201700259","article-title":"The role of mass spectrometry and proteogenomics in the advancement of HLA epitope prediction","volume":"18","author":"Creech","year":"2018","journal-title":"Proteomics"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104897_bib21","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.nmd.2014.06.436","article-title":"An analysis of the sensitivity and specificity of MHC-I and MHC-II immunohistochemical staining in muscle biopsies for the diagnosis of inflammatory myopathies","volume":"24","author":"Cruz","year":"2014","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.critrevonc.2025.104897_bib22","doi-asserted-by":"crossref","unstructured":"Darabi, A., C. Thuring, and K.M. Paulsson, HLA-I antigen presentation and tapasin influence immune responses against malignant brain tumors\u2013considerations for successful immunotherapy. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 2014. 14(8): p. 1094-1100.","DOI":"10.2174\/1871520614666140825110001"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104897_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/MOU.0000000000000462","article-title":"Prostate cancer immunotherapy: where are we and where are we going?","volume":"28","author":"De Velasco","year":"2018","journal-title":"Curr. Opin. Urol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104897_bib24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41577-020-0390-6","article-title":"A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion","volume":"21","author":"Dersh","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104897_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104897_bib26","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3390\/immuno4040028","article-title":"Mechanisms of immune evasion in PTEN loss prostate cancer","volume":"4","author":"Esteban-Villarrubia","year":"2024","journal-title":"Immuno"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104897_bib27","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.3390\/cancers12071752","article-title":"Immunotherapy in prostate cancer","volume":"12","author":"Fay","year":"2020","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104897_bib28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ijc.29375","article-title":"Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype","volume":"138","author":"Garrido","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104897_bib29","volume":"1151","author":"Garrido","year":"2019"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104897_bib30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/imm.13114","article-title":"Cancer immune escape: MHC expression in primary tumours versus metastases","volume":"158","author":"Garrido","year":"2019","journal-title":"Immunology"},{"key":"10.1016\/j.critrevonc.2025.104897_bib31","article-title":"Autophagy-dependent regulation of MHC-I molecule presentation","author":"Gestal-Mato","year":"2023","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.critrevonc.2025.104897_bib32","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/BF00661093","article-title":"Reptilian class I major histocompatibility complex genes reveal conserved elements in class I structure","volume":"36","author":"Grossberger","year":"1992","journal-title":"Immunogenetics"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104897_bib33","doi-asserted-by":"crossref","first-page":"ltad028","DOI":"10.1093\/immadv\/ltad028","article-title":"Strategies to overcome low MHC-I expression in paediatric and adult tumours","volume":"4","author":"Guillaume","year":"2024","journal-title":"Immunother. Adv."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104897_bib34","doi-asserted-by":"crossref","first-page":"ltad028","DOI":"10.1093\/immadv\/ltad028","article-title":"Strategies to overcome low MHC-I expression in paediatric and adult tumours","volume":"4","author":"Guillaume","year":"2024","journal-title":"Immunother. Adv."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104897_bib35","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2217\/fon-2017-0531","article-title":"Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions","volume":"14","author":"Handy","year":"2017","journal-title":"Future Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2025.104897_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70294","article-title":"Immunotherapy vaccines for prostate cancer treatment","volume":"13","author":"He","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2025.104897_bib37","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00424-006-0083-4","article-title":"Intracellular peptide transporters in human\u2013compartmentalization of the \u201cpeptidome","volume":"453","author":"Herget","year":"2007","journal-title":"Pfl\u00fcgers Arch. Eur. J. Physiol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104897_bib38","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1046\/j.1365-2567.2003.01738.x","article-title":"The MHC class I antigen presentation pathway: strategies for viral immune evasion","volume":"110","author":"Hewitt","year":"2003","journal-title":"Immunology"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104897_bib39","first-page":"3885","article-title":"Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic t lymphocytes","volume":"8","author":"Horiguchi","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104897_bib40","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1158\/2159-8290.CD-22-1125","article-title":"Addressing tumor heterogeneity by sensitizing resistant cancer cells to t cell\u2013Secreted cytokines","volume":"13","author":"Ito","year":"2023","journal-title":"Cancer Discov."},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104897_bib41","doi-asserted-by":"crossref","first-page":"7596","DOI":"10.1158\/1078-0432.CCR-17-0618","article-title":"Mutational analysis of gene fusions predicts novel MHC class I\u2013Restricted T-Cell epitopes and immune signatures in a subset of prostate cancer","volume":"23","author":"Kalina","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104897_bib42","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104897_bib43","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.juro.2007.03.109","article-title":"Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition","volume":"178","author":"Kitamura","year":"2007","journal-title":"J. Urol."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.104897_bib44","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1158\/0008-5472.CAN-17-3752","article-title":"Epithelial\u2013mesenchymal transition in human prostate cancer demonstrates enhanced immune evasion marked by IDO1 expression","volume":"78","author":"Kolijn","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104897_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217432","article-title":"Mechanisms of low MHC I expression and strategies for targeting MHC I with small molecules in cancer immunotherapy","volume":"611","author":"Kong","year":"2025","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104897_bib46","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.4049\/jimmunol.1900475","article-title":"Frequent loss of IRF2 in cancers leads to immune evasion through decreased MHC class I antigen presentation and increased PD-L1 expression","volume":"203","author":"Kriegsman","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104897_bib47","doi-asserted-by":"crossref","unstructured":"Lautert-Dutra, W., et al., Quantitative MHC class-I\/-II gene expression levels in CDK12 mutated prostate cancer reveal intratumorally T cell adaptive immune response in tumors. bioRxiv, 2022: p. 2022.04. 16.487364.","DOI":"10.1101\/2022.04.16.487364"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104897_bib48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13039-024-00680-6","article-title":"Loss of heterozygosity impacts MHC expression on the immune microenvironment in CDK12-mutated prostate cancer","volume":"17","author":"Lautert-Dutra","year":"2024","journal-title":"Mol. Cytogenet."},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104897_bib49","doi-asserted-by":"crossref","first-page":"10546","DOI":"10.3390\/ijms251910546","article-title":"Bioinformatic-experimental screening uncovers multiple targets for increase of MHC-I expression through activating the interferon response in breast cancer","volume":"25","author":"Li","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104897_bib50","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.immuni.2022.04.016","article-title":"Dendritic cells can prime anti-tumor CD8+ t cell responses through major histocompatibility complex cross-dressing","volume":"55","author":"MacNabb","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2025.104897_bib51","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.critrevonc.2017.02.026","article-title":"A comprehensive review of immunotherapies in prostate cancer","volume":"113","author":"Maia","year":"2017","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"20","key":"10.1016\/j.critrevonc.2025.104897_bib52","doi-asserted-by":"crossref","first-page":"15398","DOI":"10.3390\/ijms242015398","article-title":"Association of HLA-A* 11: 01,-A* 24: 02, and-B* 18: 01 with prostate cancer risk: a case-control study","volume":"24","author":"Manca","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.104897_bib53","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"20","key":"10.1016\/j.critrevonc.2025.104897_bib54","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.vaccine.2010.03.007","article-title":"IFN-\u03b3-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer","volume":"28","author":"Martini","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.critrevonc.2025.104897_bib55","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11523-015-0396-3","article-title":"Magnitude of PD-1, PD-L1 and t lymphocyte expression on tissue from castration-resistant prostate adenocarcinoma: an exploratory analysis","volume":"11","author":"Massari","year":"2016","journal-title":"Target. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104897_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2024.102209","article-title":"Downregulation of MHC-I on melanoma cells and decreased CD8+ T-Cell infiltration are associated with metastatic spread and resistance to immunotherapy","volume":"105","author":"Mengoni","year":"2025","journal-title":"Lab. Investig."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104897_bib57","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13046-022-02255-y","article-title":"Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation","volume":"41","author":"Merkens","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104897_bib58","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3390\/cells9051073","article-title":"Morphologic, molecular and clinical features of aggressive variant prostate cancer","volume":"9","author":"Montironi","year":"2020","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104897_bib59","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/joim.12470","article-title":"The immune system and cancer evasion strategies: therapeutic concepts","volume":"279","author":"Muenst","year":"2016","journal-title":"J. Intern. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104897_bib60","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/pros.20432","article-title":"MHC class I and class II molecules are expressed in both human and mouse prostate tumor microenvironment","volume":"66","author":"Nanda","year":"2006","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104897_bib61","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/pros.10136","article-title":"Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC","volume":"53","author":"Neeley","year":"2002","journal-title":"Prostate"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104897_bib62","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.4049\/jimmunol.1103136","article-title":"NLRC5 controls basal MHC class I gene expression in an MHC enhanceosome-dependent manner","volume":"188","author":"Neerincx","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104897_bib63","first-page":"OF1","article-title":"Evaluating immune checkpoint blockade in metastatic Castration-Resistant prostate cancers with deleterious CDK12 alterations in the phase 2 IMPACT trial","author":"Nguyen","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104897_bib64","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.4049\/jimmunol.1003933","article-title":"Primordial linkage of \u03b22-microglobulin to the MHC","volume":"186","author":"Ohta","year":"2011","journal-title":"J. Immunol."},{"issue":"_2","key":"10.1016\/j.critrevonc.2025.104897_bib65","first-page":"S254","article-title":"Major histocompatibility complex and mate choice in sand lizards","volume":"270","author":"Olsson","year":"2003","journal-title":"Proc. R. Soc. Lond. Ser. B Biol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104897_bib66","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41392-022-00962-8","article-title":"Integrating single-cell RNA sequencing with spatial transcriptomics reveals immune landscape for interstitial cystitis","volume":"7","author":"Peng","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104897_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114003","article-title":"Hippo-signaling-controlled MHC class I antigen processing and presentation pathway potentiates antitumor immunity","volume":"43","author":"Peng","year":"2024","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104897_bib68","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/CJI.0000000000000063","article-title":"A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A* 0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer","volume":"38","author":"Prue","year":"2015","journal-title":"J. Immunother."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104897_bib69","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41585-023-00739-w","article-title":"Vaccines as treatments for prostate cancer","volume":"20","author":"Rastogi","year":"2023","journal-title":"Nat. Rev. Urol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104897_bib70","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.3390\/cells9092051","article-title":"Is there a role for immunotherapy in prostate cancer?","volume":"9","author":"Rizzo","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104897_bib71","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s42003-022-03843-6","article-title":"Reversible epigenetic alterations regulate class I HLA loss in prostate cancer","volume":"5","author":"Rodems","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.critrevonc.2025.104897_bib72","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3389\/fimmu.2018.00102","article-title":"MHC intratumoral heterogeneity May predict cancer progression and response to immunotherapy","volume":"9","author":"Romero","year":"2018","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104897_bib73","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2326-6066.CIR-20-0729","article-title":"Flightless I homolog reverses enzalutamide resistance through PD-L1\u2013Mediated immune evasion in prostate cancer","volume":"9","author":"Ruan","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2025.104897_bib74","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.yexmp.2019.04.010","article-title":"Race-associated expression of MHC class I polypeptide-related sequence a (MICA) in prostate cancer","volume":"108","author":"Sakiyama","year":"2019","journal-title":"Exp. Mol. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104897_bib75","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13046-024-03187-5","article-title":"IRF2 loss is associated with reduced MHC I pathway transcripts in subsets of most human cancers and causes resistance to checkpoint immunotherapy in human and mouse melanomas","volume":"43","author":"Sari","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104897_bib76","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.4161\/hv.20988","article-title":"Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer","volume":"8","author":"Sasada","year":"2012","journal-title":"Hum. Vaccin. Immunother."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104897_bib77","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.urology.2013.01.061","article-title":"Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the immunotherapy for prostate adenocarcinoma treatment (IMPACT) trial","volume":"81","author":"Schellhammer","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2025.104897_bib78","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00262-009-0769-5","article-title":"Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer","volume":"59","author":"Seliger","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2025.104897_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.910595","article-title":"Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies","volume":"13","author":"Seliger","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104897_bib80","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s40364-024-00692-9","article-title":"mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy","volume":"12","author":"Shariati","year":"2024","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104897_bib81","doi-asserted-by":"crossref","DOI":"10.1111\/aji.12779","article-title":"Genetic and epigenetic regulation of major histocompatibility complex class I gene expression in bovine trophoblast cells","volume":"79","author":"Shi","year":"2018","journal-title":"Am. J. Reprod. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104897_bib82","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.bbcan.2018.06.006","article-title":"EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers","volume":"1870","author":"Soundararajan","year":"2018","journal-title":"Biochimica et Biophysica Acta (BBA)Reviews Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104897_bib83","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.3390\/cancers12061623","article-title":"HLA class I allele expression and clinical outcome in de novo metastatic prostate cancer","volume":"12","author":"Stokidis","year":"2020","journal-title":"Cancers"},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104897_bib84","doi-asserted-by":"crossref","first-page":"14454","DOI":"10.3390\/ijms241914454","article-title":"The prognostic significance of selected HLA alleles on prostate cancer outcome","volume":"24","author":"Stokidis","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.104897_bib85","doi-asserted-by":"crossref","first-page":"1410102","DOI":"10.3389\/fcell.2024.1410102","article-title":"Prostate cancer stem cells and their targeted therapies","volume":"12","author":"Su","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104897_bib86","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104897_bib87","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1158\/2159-8290.CD-23-0519","article-title":"NKG2A is a therapeutic vulnerability in immunotherapy resistant MHC-I heterogeneous triple-negative breast cancer","volume":"14","author":"Taylor","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.104897_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.844866","article-title":"Mechanisms of MHC-I downregulation and role in immunotherapy response","volume":"13","author":"Taylor","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104897_bib89","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3390\/cancers5020569","article-title":"Immunotherapy and immune evasion in prostate cancer","volume":"5","author":"Thakur","year":"2013","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104897_bib90","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.coi.2021.02.004","article-title":"MHC I assembly and peptide editing\u2014chaperones, clients, and molecular plasticity in immunity","volume":"70","author":"Thomas","year":"2021","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104897_bib91","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13148-024-01698-8","article-title":"Epigenetic regulation of major histocompatibility complexes in gastrointestinal malignancies and the potential for clinical interception","volume":"16","author":"Tovar Perez","year":"2024","journal-title":"Clin. Epigenetics"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104897_bib92","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1146\/annurev-biophys-121219-081643","article-title":"Multifunctional chaperone and quality control complexes in adaptive immunity","volume":"49","author":"Trowitzsch","year":"2020","journal-title":"Annu. Rev. Biophys."},{"key":"10.1016\/j.critrevonc.2025.104897_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215712","article-title":"Epithelial-to-mesenchymal transition hinders interferon-\u03b3-dependent immunosurveillance in lung cancer cells","volume":"539","author":"Tseng","year":"2022","journal-title":"Cancer Lett."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104897_bib94","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.3390\/cancers13092187","article-title":"Immune checkpoint inhibitors in prostate cancer","volume":"13","author":"Venkatachalam","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104897_bib95","series-title":"in Seminars in cancer biology","article-title":"Immune evasion in cancer: mechanistic basis and therapeutic strategies","author":"Vinay","year":"2015"},{"key":"10.1016\/j.critrevonc.2025.104897_bib96","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fimmu.2019.00603","article-title":"The tumor immune contexture of prostate cancer","volume":"10","author":"Vitkin","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104897_bib97","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.750022","article-title":"Cross-talk between tumor cells undergoing epithelial to mesenchymal transition and natural killer cells in tumor microenvironment in colorectal cancer","volume":"9","author":"Vuleti\u0107","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104897_bib98","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1007\/s00262-006-0157-3","article-title":"Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma","volume":"55","author":"Waeckerle-Men","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104897_bib99","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.4049\/jimmunol.2000992","article-title":"The crystal structure of the MHC class I (MHC-I) molecule in the Green anole lizard demonstrates the unique MHC-I system in reptiles","volume":"206","author":"Wang","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104897_bib100","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.actbio.2023.07.018","article-title":"Tumor acidity-activatable macromolecule autophagy inhibitor and immune checkpoint blockade for robust treatment of prostate cancer","volume":"168","author":"Wang","year":"2023","journal-title":"Acta Biomater."},{"key":"10.1016\/j.critrevonc.2025.104897_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.it.2024.01.009","article-title":"Targeting MHC-I inhibitory pathways for cancer immunotherapy","author":"Wang","year":"2024","journal-title":"Trends Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104897_bib102","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009126","article-title":"Spatial colocalization and combined survival benefit of natural killer and CD8 t cells despite profound MHC class I loss in non-small cell lung cancer","volume":"12","author":"Wessel","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104897_bib103","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fimmu.2014.00191","article-title":"Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens","volume":"5","author":"Westdorp","year":"2014","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104897_bib104","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/PO.20.00097","article-title":"Dickkopf-1 can lead to immune evasion in metastatic castration-resistant prostate cancer","author":"Wise","year":"2020","journal-title":"JCO Precis. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104897_bib105","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1172\/JCI200422206","article-title":"Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer","volume":"114","author":"Wu","year":"2004","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.critrevonc.2025.104897_bib106","article-title":"Structural comparison between MHC classes I and II; in evolution, a class-II-like molecule probably came first","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104897_bib107","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12943-023-01899-4","article-title":"Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects","volume":"22","author":"Wu","year":"2023","journal-title":"Mol. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104897_bib108","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41571-023-00789-4","article-title":"Antigen presentation in cancer\u2014mechanisms and clinical implications for immunotherapy","volume":"20","author":"Yang","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104897_bib109","doi-asserted-by":"crossref","first-page":"5999","DOI":"10.1073\/pnas.1602069113","article-title":"NLRC5\/MHC class I transactivator is a target for immune evasion in cancer","volume":"113","author":"Yoshihama","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104897_bib110","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.trecan.2016.12.003","article-title":"NLRC5\/CITA: a key player in cancer immune surveillance","volume":"3","author":"Yoshihama","year":"2017","journal-title":"Trends Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104897_bib111","article-title":"The impact of killer cell immunoglobulin-like receptor (KIR) genes and human leukocyte antigen (HLA) class I ligands on predisposition or protection against prostate cancer","volume":"228","author":"Zamir","year":"2023","journal-title":"Immunobiology"},{"key":"10.1016\/j.critrevonc.2025.104897_bib112","doi-asserted-by":"crossref","first-page":"1271449","DOI":"10.3389\/fimmu.2023.1271449","article-title":"Case report: targeting of individual somatic tumor mutations by multipeptide vaccination tailored for HLA class I and II presentation induces strong CD4 and CD8 T-cell responses in a patient with metastatic castration sensitive prostate cancer","volume":"14","author":"Zelba","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104897_bib113","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00002371-200105000-00002","article-title":"MHC class II\u2013restricted tumor antigens recognized by CD4+ t cells: new strategies for cancer vaccine design","volume":"24","author":"Zeng","year":"2001","journal-title":"J. Immunother."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104897_bib114","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13046-022-02243-2","article-title":"RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion","volume":"41","author":"Zhang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104897_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116036","article-title":"Cediranib enhances the transcription of MHC-I by upregulating IRF-1","volume":"221","author":"Zhang","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.critrevonc.2025.104897_bib116","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s12026-019-09111-w","article-title":"Promotion on NLRC5 upregulating MHC-I expression by IFN-\u03b3 in MHC-I\u2013deficient breast cancer cells","volume":"67","author":"Zhao","year":"2019","journal-title":"Immunol. Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104897_bib117","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.4161\/hv.26088","article-title":"Advances in the study of HLA-restricted epitope vaccines","volume":"9","author":"Zhao","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104897_bib118","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13046-024-03060-5","article-title":"Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells","volume":"43","author":"Zhong","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104897_bib119","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1038\/s41467-022-35130-7","article-title":"Engineered lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy","volume":"13","author":"Zhu","year":"2022","journal-title":"Nat. Commun."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:24:46Z","timestamp":1792985086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825002859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":119,"alternative-id":["S1040842825002859"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104897","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of the major histocompatibility complex (MHC) class I in prostate cancer therapy: A review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104897","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104897"}}